The year 2022 was marked by the development of numerous new treatments for refractory myasthenia gravis. The link between epilepsy and cerebrovascular disorder was studied and lamotrigine discovered to be the optimal treatment choice for epilepsy secondary to stroke to prevent mortality on patient of 45 years and older. New randomized study finally demonstrated the utility of thrombectomy in selected patients with basilar artery occlusion. The causal relationship between Epstein-Barr infection and multiple sclerosis has been proved thanks to a large cohort study. A new possibility of subcutaneous continuous levodopa administration gave promising result. Finally, numerous studies confirmed the efficacy and excellent tolerability of anti-CGRP antibodies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.53738/REVMED.2023.19.809-10.42 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impulse control disorders in Parkinson's disease: What's new?
J Neurol
January 2025
Parkinson's Disease Research Clinic, Macquarie University, 75 Talavera Road, Sydney, NSW, 2109, Australia.
Impulse Control Disorders (ICDs) are increasingly recognized as a significant non-motor complication in Parkinson's disease (PD), impacting patients and their caregivers. ICDs in PD are primarily associated with dopaminergic treatments, particularly dopamine agonists, though not all patients develop these disorders, indicating a role for genetic and other clinical factors. Studies over the past few years suggest that the mesocorticolimbic reward system, a core neural substrate for impulsivity, is a key contributor to ICDs in PD.
View Article and Find Full Text PDF[Neurology: what's new in 2024].
Rev Med Suisse
January 2025
Service de neurologie, Département des neurosciences cliniques, Centre hospitalier universitaire vaudois et Université de Lausanne, 1011 Lausanne.
In 2024, therapeutic and diagnostic advancements are shaping the field of neurology. Three new drugs show promise for treating myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. A new classification for Parkinson's disease has been proposed, while a neuroprosthesis is improving gait in advanced stages.
View Article and Find Full Text PDFWhat's in a Name: Your PLEX or PEX Is Our TPE.
J Clin Apher
December 2024
Department of Pathology and Genomic Medicine, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA.
In the American Society for Apheresis (ASFA) guidelines, the abbreviation for therapeutic plasma exchange is standardized as TPE. However, the term PLEX (derived from PLasma EXchange), among others, is not infrequently encountered in clinical practice and in publications. Search queries were performed in PubMed using therapeutic plasma exchange, plasma exchange, "therapeutic plasma exchange," "plasma exchange," TPE plasma, PLEX plasma, PEX plasma, TPE, PLEX, and PEX.
View Article and Find Full Text PDFAlzheimer Disease-What's in a Name?
JAMA Neurol
December 2024
Departments of Pathology and Neurological Sciences, Rush University Medical Center, Chicago, Illinois.
What's in It for Me? Contextualizing the Potential Clinical Impacts of Lecanemab, Donanemab, and Other Anti-β-amyloid Monoclonal Antibodies in Early Alzheimer's Disease.
eNeuro
September 2024
Department of Neurology, Taub Institute for Research on Alzheimer's Disease and the Aging Brain, and the GH Sergievsky Center, Columbia University Irving Medical Center, New York, New York 10032
Article Synopsis
- The FDA approved aducanumab in 2021, marking a significant breakthrough in Alzheimer's disease treatment, with two more drugs, lecanemab and donanemab, receiving similar approvals in early 2023 and mid-2024.
- These therapies, which target β-amyloid aggregates, have shown promising results in slowing cognitive decline in clinical trials.
- Ongoing discussions focus on the application of trial results to real-world scenarios and the overall long-term benefits of these treatments, along with the implications of FDA approval conditions on their usage in clinical practice.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!